Cytokinetics Clears Technical Benchmark, Hitting 80-Plus RS Rating
| CYTK Stock | USD 52.22 0.20 0.38% |
About 53% of Cytokinetics' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cytokinetics suggests that some traders are interested. Cytokinetics' investing sentiment shows overall attitude of investors towards Cytokinetics.
Cytokinetics |
Cytokinetics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.
Read at investors.com
 |
Cytokinetics Current Investor Sentiment
Panic Vs Confidence
53
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Cytokinetics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Cytokinetics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Cytokinetics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cytokinetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cytokinetics Historical Investor Sentiment
Investor biases related to Cytokinetics' public news can be used to forecast risks associated with an investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Cytokinetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Cytokinetics.
Cytokinetics Fundamental Analysis
We analyze Cytokinetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Cytokinetics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Cytokinetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytokinetics stock to make a market-neutral strategy. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics with similar companies.
Peers
Cytokinetics Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| ARVN | Arvinas | 6.13 | ||||
| BDTX | Black Diamond | 3.11 | ||||
| EWTX | Edgewise Therapeutics | 2.48 | ||||
| PLRX | Pliant Therapeutics | 2.00 | ||||
| STOK | Stoke Therapeutics | 1.68 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| RVMD | Revolution Medicines | 1.25 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| DYN | Dyne Therapeutics | 1.67 | ||||
| RLAY | Relay Therapeutics | 2.08 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 |
Check out Cytokinetics Hype Analysis, Cytokinetics Correlation and Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.